KYC is one time exercise with a SEBI registered intermediary while dealing in securities markets (Broker/ DP/ Mutual Fund etc.). | No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.   |   Prevent unauthorized transactions in your account – Update your mobile numbers / email ids with your stock brokers. Receive information of your transactions directly from exchange on your mobile / email at the EOD | Filing Complaint on SCORES - QUICK & EASY a) Register on SCORES b) Mandatory details for filing complaints on SCORE - Name, PAN, Email, Address and Mob. no. c) Benefits - speedy redressal & Effective communication   |   BSE Prices delayed by 5 minutes...<< Prices as on Feb 01, 2026 - 3:59PM >>  ABB India 5428.6  [ -2.66% ]  ACC 1622.15  [ -0.94% ]  Ambuja Cements 497.3  [ -2.53% ]  Asian Paints 2359  [ -2.87% ]  Axis Bank 1338.35  [ -2.33% ]  Bajaj Auto 9486  [ -1.11% ]  Bank of Baroda 279.6  [ -6.60% ]  Bharti Airtel 1946.25  [ -1.11% ]  Bharat Heavy 251.95  [ -4.15% ]  Bharat Petroleum 358.9  [ -1.40% ]  Britannia Industries 5722.75  [ -2.28% ]  Cipla 1325.85  [ 0.14% ]  Coal India 419.15  [ -4.83% ]  Colgate Palm 2096.4  [ -0.81% ]  Dabur India 503  [ -0.76% ]  DLF 613.8  [ -3.37% ]  Dr. Reddy's Labs 1182.75  [ -2.93% ]  GAIL (India) 162.3  [ -2.90% ]  Grasim Industries 2745.45  [ -2.61% ]  HCL Technologies 1668.5  [ -1.53% ]  HDFC Bank 920.2  [ -0.98% ]  Hero MotoCorp 5508.1  [ -0.49% ]  Hindustan Unilever 2351.15  [ -0.95% ]  Hindalco Industries 907.6  [ -5.66% ]  ICICI Bank 1333.5  [ -1.59% ]  Indian Hotels Co. 661.85  [ -1.88% ]  IndusInd Bank 896.35  [ 0.11% ]  Infosys 1659.65  [ 1.17% ]  ITC 309.6  [ -3.91% ]  Jindal Steel 1102.7  [ -2.48% ]  Kotak Mahindra Bank 407.6  [ -0.10% ]  L&T 3813  [ -3.06% ]  Lupin 2122.6  [ -1.32% ]  Mahi. & Mahi 3363.25  [ -2.01% ]  Maruti Suzuki India 14200.7  [ -2.75% ]  MTNL 32.21  [ -5.21% ]  Nestle India 1271.45  [ -4.51% ]  NIIT 77.47  [ 3.46% ]  NMDC 80.38  [ -0.95% ]  NTPC 345.6  [ -2.87% ]  ONGC 254.3  [ -5.45% ]  Punj. NationlBak 121.55  [ -2.92% ]  Power Grid Corpo 251.05  [ -2.07% ]  Reliance Industries 1346  [ -3.57% ]  SBI 1017.15  [ -5.61% ]  Vedanta 654.85  [ -4.08% ]  Shipping Corpn. 213.9  [ -5.14% ]  Sun Pharmaceutical 1610.2  [ 0.95% ]  Tata Chemicals 743.25  [ -0.41% ]  Tata Consumer Produc 1092.3  [ -3.67% ]  Tata Motors Passenge 344.5  [ -1.56% ]  Tata Steel 185.6  [ -3.88% ]  Tata Power Co. 354.15  [ -3.40% ]  Tata Consultancy 3185.15  [ 1.92% ]  Tech Mahindra 1715.65  [ -1.59% ]  UltraTech Cement 12285.9  [ -3.26% ]  United Spirits 1338.55  [ -1.82% ]  Wipro 242.05  [ 2.26% ]  Zee Entertainment En 81.54  [ -3.23% ]  
  • Share Prices
  • Tools
  • News
  • Company Details
  • Financial Data
  • Results
  • Key Financial Ratios
  • Reports
  • Corporate Announcements
  • Equity History

    • Company Information

    Indian Indices
    • Loading....

    Global Indices
    • Loading....

    Forex
    • Loading....

    SUN PHARMA ADVANCED RESEARCH COMPANY LTD.

    01 February 2026 | 04:09

    Industry >> Medical Research Services

    Select Another Company

    ISIN No INE232I01014 BSE Code / NSE Code 532872 / SPARC Book Value (Rs.) -10.62 Face Value 1.00
    Bookclosure 30/09/2020 52Week High 204 EPS 0.00 P/E 0.00
    Market Cap. 4335.61 Cr. 52Week Low 109 P/BV / Div Yield (%) -12.58 / 0.00 Market Lot 1.00
    Security Type Other

    History of Company

    The company history sections lists out major chronological events that happened to the company.
    2007 - Sun Pharma Advanced Research Co.Ltd was formed in the year 2007, with separation of India's leading specialty pharma company, Sun Pharmaceutical Industries Ltd, and its active projects in drug discovery and innovation into a new company. The parent company, Sun Pharma Industries Ltd continues to invest independently in generic research.

    - Sun Pharma Advanced Research Company Ltd (SPARCL) had allotted 3,39,441 equity shares of Re 1 each to the bond-holders of Sun Pharma Industries Ltd (SPIL) on conversion of 5,500 foreign currency convertible bonds upon conversion.

    - Balance Sheet along with the Profit and Loss Account for the year ended March 31, 2007 adopted and the Reports of Directors & Auditors thereon.

    - Mr. Dilip S Shanghvi and Mr. Sudhir V Valia, re appointed as the Directors of the Company.

    - According to the clause 10.2 of the scheme of arrangement of demerger, sanctioned by the High Court of Gujarat through its order dated March 01, 2007, issued on March 28, 2007 and as per supplementary Trust Deed dated may 18, 2007, the FCCB's holders of Sun Pharma Industries Ltd, are entitled for one equity share of Re 1 each of the company for every equity share of Rs.5 each of SPIL.

    2011

    - "Sun Pharma announces USFDA approval for DOCEFREZ (docetaxel) for Injection".

    2012

    -SPARC - Starhaler Device finalist at Medical Design Excellence Awards

    -Sun Pharma Advanced Research Company Ltd Issues Rights in the Ratio of 1:7

    2013 -SPARC to provide update on NCE & NDDS programs

    2014 -SPARC Announces India Approval for Paclitaxel Injection Concentrate for Nanodispersion (PICN)

    2017 - SPARC has received a Complete Response Letter (CRL) from the USFDA for its New Drug Application (NDA) for Elepsia XRTM, Levetiracetam extended-release tablets 1000 mg and 1500 mg.

    2018 -SPARC to provide progress on R&D Pipeline -Sun Pharma and SPARC Announce US FDA Approval of XELPROS to Treat Open-angle Glaucoma or Ocular Hypertension -SPARC Announces Top-line Results of Pivotal Bioequivalence Study for Paclitaxel Injection Concentrate for Suspension -Schr”dinger and SPARC Announce Collaboration to Accelerate Neurodegeneration Drug Development Program

    2019 -SPARC Enters into Licensing Agreement with Bioprojet to Acquire Exclusive Rights for Investigational -HitGen and SPARC Enter DNA-Encoded Library Based Innovative Drug Discovery Research Collaboration -SPARC Receives Orphan Drug Designation from the USFDA for SCO-088 for the Treatment of Patients with Chronic Myeloid Leukemia -SPARC Enters into a Licensing Deal with CMS -SPARC Enters into Licensing Agreement with Bioprojet to Acquire Exclusive Rights for Investigational Medicinal Product, SCD-044 2020 -Sun Pharma Advanced Research Company Ltd grant of an exclusive license to Tripoint Therapeutics LLC to commercialize ElepsiaTM XR 1000 mg and ElepsiaTM XR 1500 mg tablets in the USA. -Sun Pharma Advanced Research Company Ltd got positive top-line results from its Phase 3 trial for its investigational drug, SDN-037, for the treatment of Inflammation and Pain associated with Ocular Surgery -SPARC to Provide Update on Clinical Programs and R&D Pipeline

    2021 -SPARC enters into a licensing agreement with Biomodifying to acquire exclusive rights for antibody against unique oncology target -Sun Pharma Advanced Research Company Ltd has entered into an agreement with Visiox Pharma LLC to grant exclusive worldwide rights for the development and commercialization of PDP-716 and SDN-037

    2022 -Sun Pharma and SPARC enter into a license agreement for commercialization of phenobarbital for injection in the US.

    2023 -Entered into licensing agreement to acquire exclusive rights for SCD-153. -Formation of US subsidiary.

    Way2Wealth Brokers Private Limited - CIN U67120KA2000PTC027628 Stock Broking: SEBI Regn No.: INZ000178638 | Exchange Membership ID: NSE: 11502, BSE: 3117, MSEI:51000, MCX: 56730 Depository Participant: SEBI Regn No. IN-DP-472-2020 | CDSL ID: 12062900 & 12031500, NSDL ID: IN303077 | Research Analyst: SEBI Regn No. INH200008705 | PMS: SEBI Regn No.INP000000829 | Register with AMFI ARN: 77558 (Date of Initial registration - 8th Dec 2009, Date of expiry - 24th Jan 2027) | PFRDA: POP226012019

    Way2Wealth Commodities Private Limited - CIN U51229KA2006PTC039880 Stock Broking: SEBI Regn No.: INZ000049130 | Exchange Membership ID: NCDEX : 00908

    Copyrights @ 2014 © Way2Wealth Brokers Pvt. Ltd. All rights reserved

    Designed, developed and content provided by  Dion

    Procedure to file a complaint on SEBI SCORES: Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances.